BRANFORD, Conn. / Nov 01, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in two upcoming investor conferences:
About the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Quantum-Si management will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place at the Westin NY Grand Central on Thursday, November 16, 2023.
Jeff Hawkins, Chief Executive Officer of Quantum-Si, will participate in a fireside chat on Thursday, November 16, at 4:30 – 4:55 p.m. Eastern Time.
About the 6th Annual Evercore ISI HealthCONx Conference
Quantum-Si management will attend the 6th Annual Evercore ISI HealthCONx Conference, taking place at the Kimpton Epic Hotel in Miami, Florida on November 28-30, 2023.
Jeff Hawkins will participate in a fireside chat on Wednesday, November 29, at 7:55 – 8:15 a.m. Eastern Time.
Where to View
A live and archived webcast of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.
| Last Trade: | US$1.27 |
| Daily Change: | 0.05 4.10 |
| Daily Volume: | 5,478,191 |
| Market Cap: | US$248.350M |
November 20, 2025 November 05, 2025 September 23, 2025 September 08, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
